NUCLIDIUM 84 million euros for radiopharmaceuticals

The biotech NUCLIDIUM AG has closed a Series B financing round of 84 million euros. The round was led by a broad consortium of international investors, including Bayern Kapital, Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners and other renowned investors.

Focus on copper-based radiotheranostics

NUCLIDIUM develops copper-based radiopharmaceuticals for the targeted diagnosis and treatment of tumors. The company's platform uses the isotopes copper-61 for imaging and copper-67 for therapeutic applications. Initial clinical data indicate improved imaging for metastatic prostate cancer, neuroendocrine tumors and breast cancer.

We are now entering the next clinical phases with our first compounds for the diagnosis and treatment of metastatic prostate cancer, neuroendocrine tumors and breast cancer.

Dr. Leila Jaafar, CEO and co-founder of NUCLIDIUM AG

Funds for clinical development and production expansion

The fresh capital will be used to expand the clinical pipeline and build up global production capacities. At the same time, NUCLIDIUM intends to expand strategic partnerships with clinics and research institutions, particularly in Europe and North America.

Investors focus on scalable solution

Not only is the data from the first clinical trials of NUCLIDIUM's active ingredients promising, the company also has an experienced, interdisciplinary team with extensive technical expertise.

Monika Steger, Managing Director of Bayern Kapital

In addition to clinical progress, the company impressed with its proprietary, scalable manufacturing process. This is intended to address challenges in radiopharmacy, such as security of supply and sustainability. Bayern Kapital sees NUCLIDIUM as a promising investment in the growing precision oncology market.